CervoMed Inc. (CRVO) News
Follow CervoMed Inc. (CRVO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 21 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
CervoMed Reports Q3 2026 Net Loss of $5.9 Million
CervoMed reported a third-quarter 2026 net loss of approximately $5.9 million, down from $7.7 million a year earlier. It ended September with $19.6 million in cash, cash equivalents and marketable securities, and said re
EQUITY | Nov 09, 2026, 09:21 PM UTC
M
CervoMed Q3 Net Loss Narrows as R&D Costs Fall
CervoMed reported a narrower third-quarter net loss as research and development costs declined following completion of its RewinD-LB trial.
EQUITY | Nov 09, 2026, 12:42 PM UTC
M
CervoMed’s Neflamapimod Fails Primary Endpoint in Phase 2b Trial
CervoMed said neflamapimod failed to meet the primary endpoint in a Phase 2b trial for Lewy body dementia.
EQUITY | Oct 29, 2026, 11:43 AM UTC
L
CervoMed unveils 50 mg tablet, FDA lifts exposure cap enabling 100 mg BID regimen
CervoMed announced a new 50 mg neflamapimod tablet with improved PK and FDA removal of the prior plasma exposure limit enabling a planned 100 mg twice-daily regimen.Key Highlights:Original SEC Filing: CervoMed Inc. [ CRV
REGULATION | Sep 28, 2026, 09:18 PM UTC
L
CervoMed Inc. (CRVO) FDA Lifts Exposure Cap; New Tablet Supports 100 mg BID
CervoMed reported a new 50 mg neflamapimod tablet with BID-friendly PK and said the FDA removed a prior plasma exposure limit, enabling plans to advance a 100 mg twice-daily regimen in future trials.Material DetailsConte
REGULATION | Sep 28, 2026, 11:32 AM UTC
L
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenienceFDA removal of the prior drug exposure limit provides greater dosing flexibility infuture clin
REGULATION | Sep 28, 2026, 11:32 AM UTC
L
CRVO - CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
CRVO - CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
NEWS | Sep 22, 2026, 11:30 AM UTC
L
CervoMed says Phase 2a nfvPPA biomarker data will be presented at ISFTD 2026
CervoMed said initial 12-week biomarker results from its Phase 2a nfvPPA trial will be presented as a late-breaking oral session at ISFTD 2026.
EQUITY | Sep 10, 2026, 08:16 PM UTC
H
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual MeetingnfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with tau pathology, curre
EQUITY | Sep 10, 2026, 11:32 AM UTC
L
CervoMed Phase 2a results accepted for late-breaking ISFTD 2026 oral
EQUITY | Sep 10, 2026, 11:30 AM UTC
L
CRVO - CervoMed to Participate in September Investor Conferences
CRVO - CervoMed to Participate in September Investor Conferences
EQUITY | Sep 08, 2026, 11:30 AM UTC
H
UK Awards CRVO's Neflamapimod Innovation Passport
CRVO's Neflamapimod awarded UK innovation passport
EQUITY | Aug 04, 2026, 09:15 AM UTC
L
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International
Latest findings on neflamapimod to be featured in presentations demonstrating its impact
EQUITY | Jul 06, 2026, 11:30 AM UTC
L
CDNL: Proposes Public Offering
CDNL proposes public offering of common stock
EQUITY | Jun 23, 2026, 09:24 AM UTC
M
CDNL: Proposes Public Offering
CDNL proposes public offering of common stock, among other equity offerings from various companies
EQUITY | Jun 22, 2026, 09:10 PM UTC
M
CRVO Raises $10M
CervoMed announces closing of $10 million registered direct offering of common stock priced at-the-market under Nasdaq rules
EQUITY | Jun 22, 2026, 08:05 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Monday's pre-market session, with gains and losses across the sector
EQUITY | Jun 22, 2026, 12:08 PM UTC
M
CRVO Raises $10M
CervoMed agreed to raise $10M in a direct stock offering of 2.5M shares at $4/share to use for working capital
EQUITY | Jun 22, 2026, 10:15 AM UTC
M
CRVO Sells Shares
CRVO sells 2,500,000 shares of common stock at $4.00 per share
EQUITY | Jun 18, 2026, 04:36 PM UTC
M
CRVO: Offers $10M Common Stock
CervoMed announces $10 million registered direct offering of common stock priced at-the-market under Nasdaq rules
EQUITY | Jun 18, 2026, 04:35 PM UTC